Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.2598
-0.0052 (-1.96%)
Streaming Delayed Price
Updated: 1:09 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
February 04, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022
February 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today
February 03, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19
Via
Benzinga
Cybin's Vision Strengthens Position In Emerging Wellness Trend
January 28, 2022
Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health...
Via
Benzinga
Cybin Schedules Release of Q3 Results, Conference Call
January 27, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
February 02, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17
Via
Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
February 01, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69
Via
Benzinga
Cybin's IRB-Approved Study Begins Enrollment This Year
February 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Upcoming study supports CYBN’s mission to develop psychedelics...
Via
Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Begins Enrollment This Year
February 01, 2022
Via
Investor Brand Network
Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants
January 31, 2022
Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants.
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33
Via
Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year
January 31, 2022
Via
Investor Brand Network
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
January 30, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57
Via
Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Position in Emerging Wellness Trend
January 28, 2022
Via
Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend
January 27, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Schedules Release of Q3 Results, Conference Call
January 27, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call
January 27, 2022
Via
Investor Brand Network
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
January 23, 2022
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry
January 19, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.